[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2007/232604,2007,A1Locationinpatent:Page/Pagecolumn40
[2]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2009/38757,2009,A2Locationinpatent:Page/Pagecolumn85-86
[3]Locationinpatent:experimentalpartChao,Qi;Sprankle,KellyG.;Grotzfeld,RobertM.;Lai,AndiliyG.;Carter,ToddA.;Velasco,AnneMarie;Gunawardane,RuwanthiN.;Cramer,MerrylD.;Gardner,MichaelF.;James,Joyce;Zarrinkar,PatrickP.;Patel,HiteshK.;Bhagwat,ShripadS.[JournalofMedicinalChemistry,2009,vol.52,#23,p.7808-7816]
[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-US2007/232604,2007,A1Locationinpatent:Page/Pagecolumn40
[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2009/38757,2009,A2Locationinpatent:Page/Pagecolumn87
[2]Chao,Qi;Sprankle,KellyG.;Grotzfeld,RobertM.;Lai,AndiliyG.;Carter,ToddA.;Velasco,AnneMarie;Gunawardane,RuwanthiN.;Cramer,MerrylD.;Gardner,MichaelF.;James,Joyce;Zarrinkar,PatrickP.;Patel,HiteshK.;Bhagwat,ShripadS.[JournalofMedicinalChemistry,2009,vol.52,#23,p.7808-7816]
[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2009/38757,2009,A2Locationinpatent:Page/Pagecolumn88
[1]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2009/38757,2009,A2Locationinpatent:Page/Pagecolumn88
[2]Locationinpatent:experimentalpartChao,Qi;Sprankle,KellyG.;Grotzfeld,RobertM.;Lai,AndiliyG.;Carter,ToddA.;Velasco,AnneMarie;Gunawardane,RuwanthiN.;Cramer,MerrylD.;Gardner,MichaelF.;James,Joyce;Zarrinkar,PatrickP.;Patel,HiteshK.;Bhagwat,ShripadS.[JournalofMedicinalChemistry,2009,vol.52,#23,p.7808-7816]
[3]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2011/56939,2011,A1Locationinpatent:Page/Pagecolumn92-93
[4]CurrentPatentAssignee:DAIICHISANKYOCOMPANY,LIMITED-WO2009/38757,2009,A2Locationinpatent:Page/Pagecolumn88-90
Title: Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
Journal: Blood 20160609
Title: BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Journal: Molecular cancer therapeutics 20141001
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Journal: Bioorganic & medicinal chemistry letters 20120715
Title: Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Journal: Leukemia 20120701
Title: Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Journal: Nature 20120415
Title: Molecular targeted therapy in acute myeloid leukemia.
Journal: Hematology (Amsterdam, Netherlands) 20120401
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
Journal: Journal of medicinal chemistry 20111027
Title: FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Journal: The oncologist 20110801
Title: FLT3 inhibitors: a story of the old and the new.
Journal: Current opinion in hematology 20110301
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Journal: Blood 20100218
Title: Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
Journal: Journal of medicinal chemistry 20091210
Title: AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Journal: Blood 20091001
Title: Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992.
Title: Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42.
Title: Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64.
